Inicio
→
Listar por autor

Listar por autor "Tabernero, Josep"

Mostrando ítems 1-11 de 11

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

Tabernero, Josep; Hozak, R.R.; Yoshino, Takayuki; Cohn, A.L.; Obermannova, R.; Bodoky, G.; Garcia Carbonero, R.; Ciuleanu, T.E.; Portnoy, D.C.; Prausova, J.; Van Cutsem, Eric (Elsevier, 2018)

Background: The phase III RAISE trial (NCT01183780) demonstrated that the vascular endothelial growth factor (VEGF) receptor (VEGFR)-2 binding monoclonal antibody ramucirumab plus 5-fluororuracil, leucovorin, and irinotecan ...
Binimetinib Encorafenib and Cetuximab Triplet Therapy for Patients With BRAF V600E-Mutant Metastatic Colorectal Cancer: Safety Lead-In Results From the Phase III BEACON Colorectal Cancer Study

Van Cutsem, Eric; Huijberts, Sanne; Grothey, Axel; Yaeger, Rona; Cuyle, Pieter-Jan; Elez, Elena; Fakih, Marwan; Montagut, Clara; Peeters, Marc; Yoshino, Takayuki; Kopetz, Scott; Tabernero, Josep (Lippincott Williams & Wilkins, 2019)

To determine the safety and preliminary efficacy of selective combination targeted therapy for BRAF V600E-mutant metastatic colorectal cancer (mCRC) in the safety lead-in phase of the open-label, randomized, three-arm, ...
Current developments in gastric cancer: from molecular profiling to treatment strategy

Alsina, Maria; Arrazubi, Virginia; Diez, Marc; Tabernero, Josep (SpringerNature, 2023)

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care challenge. Despite the efficacy of improved chemotherapy and surgical options, these patients still have a poor prognosis. In advanced ...
Efficacy and Safety of Pembrolizumab or Pembrolizumab plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial

Shitara, Kohei; Van Cutsem, Eric; Bang, Yung-Jue; Fuchs, Charles; Wyrwicz, Lucjan; Tabernero, Josep (American Medical Association, 2020)

IMPORTANCE Safe and effective therapies for untreated, advanced gastric/gastroesophageal junction (G/GEJ) cancer remain an unmet need. OBJECTIVE To evaluate the antitumor activity of pembrolizumab, pembrolizumab plus ...
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial

Montagut, Clara; Argilés, Guillem; Ciardiello, Fortunato; Poulsen, Thomas T.; Dienstmann, Rodrigo; Kragh, Michael; Kopetz, Scott; Lindsted, Trine; Ding, Cliff; Vidal, Joana; Tabernero, Josep (American Medical Association, 2018)

IMPORTANCE Acquired resistance to anti-EGFR therapy (epidermal growth factor receptor) is frequently due to RAS and EGFR extracellular domain (ECD) mutations in metastatic colorectal cancer (mCRC). Some anti-EGFR-refractory ...
Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: Updated survival results and subgroup analyses from the BEACON study

Tabernero, Josep; Grothey, Axel; Van Cutsem, Eric; Wasan, Harpreet; Yoshino, Takayuki; Desai, Jayesh; Ciardiello, Fortunato; Loupakis, Fotio; Hong, Yong Sang (American Society of Clinical Oncology, 2021)

PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC), ...
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer

Kopetz, Scott; Grothey, Axel; Yaeger, Rona; Van Cutsem, Eric; Desai, Jayesh; Yishino, Takayuki; Wasan, Harpreet; Ciardiello, Fortunato; Loupakis, Fotio; Tabernero, Josep (Massachusetts Medical Society, 2019)

Colorectal cancers with BRAF mutations have an aggressive natural history and are often resistant to therapy. A treatment regimen that combined BRAF inhibition, MET inhibition, and blocking of EGFR signaling resulted in a ...
Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines

Grothey, Axel; Fakih, Marwan; Tabernero, Josep (Elsevier, 2021)

Colorectal cancer (CRC) is still a leading cause of cancer-related deaths in the United States and worldwide, despite recent improvements in cancer management. CRC, like many malignancies, is a heterogeneous disease, ...
Multicenter Phase I Study of Erdafitinib (JNJ-42756493) Oral Pan-Fibroblast Growth Factor Receptor Inhibitor in Patients with Advanced or Refractory Solid Tumors

Bahleda, Rastislav; Italiano, Antoine; Hierro, Cinta; Mita, Alain; Cervantes, Andrés; Chan, Nancy; Awad, Mark; Moreno, Víctor; Tabernero, Josep (American Association Cancer Research, 2019)

Purpose: Here, we report results of the first phase I study of erdafitinib, a potent, oral pan-FGFR inhibitor. Patients and Methods: Patients age >= 18 years with advanced solid tumors for which standard antineoplastic ...
Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Tabernero, Josep; Hoff, Paulo M.; Shen, Lin; Ohtsu, Atsushi; Shah, Manish A.; Cheng, Karen; Song, Chunyan; Wu, Haiyan; Eng-Wong, Jennifer; Kim, Katherine; Kang, Yoon-Koo (Elsevier, 2018)

Background: Adding pertuzumab to trastuzumab and chemotherapy improves survival in HER2-positive early breast cancer and metastatic breast cancer. We assessed the efficacy and safety of pertuzumab versus placebo in combination ...
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

Hill, Andrew G.; Findlay, Michael P.; Burge, Matthew E.; Jackson, Christopher; Garcia Alfonso, Pilar; Samuel, Leslie; Ganju, Vinod; Karthaus, Meinolf; Amatu, Alessio; Tabernero, Josep (American Association Cancer Research, 2018)

Purpose: Duligotuzumab is a dual-action antibody directed against EGFR and HER3. Experimental Design: Metastatic colorectal cancer (mCRC) patients with KRAS ex2 wild-type received duligotuzumab or cetuximab and FOLFIRI ...

Mostrando ítems 1-11 de 11

Buscar en RIUVic

Búsqueda avanzada

Listar

Todo DSpace

Listar por autor "Tabernero, Josep"

Listar por autor "Tabernero, Josep"

Buscar en RIUVic

Listar

Todo DSpace